3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
167
Neoplasm Metastasis
18
Breast Neoplasms, Male
15
Neoplasms
13
Brain Neoplasms
11
Inflammatory Breast Neoplasms
5
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Osteitis Deformans
2
Lung Neoplasms
2
HER2 Positive Metastatic Breast Cancer
2
Esophageal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Ductal, Breast
2
Breast Diseases
2
Urinary Bladder Neoplasms
1
Prostatic Neoplasms
1
Patient Compliance
1
Neoplastic Cells, Circulating
1
Metastatic Breast Cancer With Intracranial Metastases
1
Invasive Breast Cancer
1
Insulin-Like Growth Factor I, Resistance To
1
Her2 Positive Metastatic Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
HER2-Positive Early Stage Breast Cancer
1
HER2+ Metastatic Breast Cancer (MBC)
1
HER2 Positive Breast Cancer
1
Interventions
Surveys and Questionnaires
7
Nivolumab
5
atezolizumab
3
Radiosurgery
3
Blood Specimen Collection
3
pertuzumab
2
pembrolizumab
2
pazopanib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Interviews as Topic
2
Drug Therapy
2
Capecitabine
2
tepotinib
1
talazoparib
1
selpercatinib
1
pralsetinib
1
ponatinib
1
pemigatinib
1
palbociclib
1
motexafin gadolinium
1
montanide ISA 51
1
mannide monooleate
1
itacitinib
1
ipatasertib
1
fludarabine
1
entrectinib
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
Lapatinib
×
Breast
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled